Inhibikase Therapeutics advances Parkinson’s disease treatment with risvodetinib clinical trials

Inhibikase Therapeutics, Inc. (Nasdaq: IKT), a clinical-stage pharmaceutical company, has announced the publication of its Phase 1 clinical studies for risvodetinib (risvo), a potential disease-modifying ... Read More